This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Gasparyan, A. Y. Articles by Lip, G. Y.H. Search for Related Content PubMed Articles by Gasparyan, A. Y. Articles by Lip, G. Y.H.

STATE-OF-THE-ART PAPER

The Role of Aspirin in Cardiovascular Prevention

Implications of Aspirin Resistance

Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, United Kingdom.

Manuscript received September 13, 2007; revised manuscript received October 19, 2007, accepted November 10, 2007.

^_* Reprint requests and correspondence: Prof. Gregory Y. H. Lip, Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, United Kingdom. (Email: g.y.h.lip{at}bham.ac.uk).

Aspirin is well recognized as an effective antiplatelet drug for secondary prevention in subjects at high risk of cardiovascular events. However, most patients receiving long-term aspirin therapy still remain at substantial risk of thrombotic events due to insufficient inhibition of platelets, specifically via the thromboxane A2 pathway. Although the exact prevalence is unknown, estimates suggest that between 5.5% and 60% of patients using this drug may exhibit a degree of "aspirin resistance," depending upon the definition used and parameters measured. To date, only a limited number of clinical studies have convincingly investigated the importance of aspirin resistance. Of these, few are of a sufficient scale, well designed, and prospective, with aspirin used at standard doses. Also, most studies do not sufficiently address the issue of noncompliance to aspirin as a frequent, yet easily preventable cause of resistance to this antiplatelet drug. This review article provides a comprehensive overview of aspirin resistance, discussing its definition, prevalence, diagnosis, and therapeutic approaches. Moreover, the clinical implications of aspirin resistance are explored in various cardiovascular disease states, including diabetes mellitus, hypertension, heart failure, and other similar disorders where platelet reactivity is enhanced.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ADP = adenosine diphosphate   CI = confidence interval   COX = cyclooxygenase   CRP = C-reactive protein   MI = myocardial infarction   NO = nitric oxide   RPFA = rapid platelet function assay

This article has been cited by other articles:

				R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. M. Gori, R. Marcucci, D. Prisco, and R. Abbate Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy Am J Clin Pathol, June 1, 2009; 131(6): 834 - 842. [Abstract] [Full Text] [PDF]

				J. Rivera, M. L. Lozano, L. Navarro-Nunez, and V. Vicente Platelet receptors and signaling in the dynamics of thrombus formation Haematologica, May 1, 2009; 94(5): 700 - 711. [Abstract] [Full Text] [PDF]

				E. I. Lev Aspirin resistance transient laboratory finding or important clinical entity? J. Am. Coll. Cardiol., February 24, 2009; 53(8): 678 - 680. [Full Text] [PDF]

				B. A. Kottke The Ultimate Solution to the Problem of Aspirin Resistance J. Am. Coll. Cardiol., October 7, 2008; 52(15): 1276 - 1276. [Full Text] [PDF]

				A. Y. Gasparyan and G. Y.H. Lip Reply J. Am. Coll. Cardiol., October 7, 2008; 52(15): 1277 - 1277. [Full Text] [PDF]

				J. R. Kapoor Enteric Coating Is a Possible Cause of Aspirin Resistance J. Am. Coll. Cardiol., October 7, 2008; 52(15): 1276 - 1277. [Full Text] [PDF]

				F. A. Ofosu, L. Dewar, S. J. Craven, Y. Song, A. Cedrone, J. Freedman, and J. W. Fenton II Coordinate Activation of Human Platelet Protease-activated Receptor-1 and -4 in Response to Subnanomolar {alpha}-Thrombin J. Biol. Chem., October 3, 2008; 283(40): 26886 - 26893. [Abstract] [Full Text] [PDF]

				D. Trenk and F.-J. Neumann Aspirin Resistance: An Underestimated Risk in Patients With Drug-Eluting Stents? J. Am. Coll. Cardiol., August 26, 2008; 52(9): 740 - 742. [Full Text] [PDF]

				P. W. Kamphuisen Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment Eur. Heart J., July 2, 2008; 29(14): 1699 - 1700. [Full Text] [PDF]